Adiponectin and Lipoprotein Particle Size
- Ram Weiss, MD, PHD1,
- James D. Otvos, PHD2,
- Allan Flyvbjerg, MD, DMSC3,
- Andre R. Miserez, MD4,5,
- Jan Frystyk, MD, PHD3,
- Ronit Sinnreich, PHD1 and
- Jeremy D. Kark, MD, PHD1
- 1Hebrew University-Hadassah Braun School of Public Health and Community Medicine, Faculty of Medicine, Jerusalem, Israel;
- 2LipoScience, Raleigh, North Carolina;
- 3Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus, Denmark;
- 4Research Laboratories, Diagene, Reinach, Switzerland;
- 5Department of Internal Medicine, University of Basel, Basel, Switzerland.
- Corresponding author: Ram Weiss, ram.weiss{at}ekmd.huji.ac.il.
Abstract
OBJECTIVE Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity.
RESEARCH DESIGN AND METHODS A cross-sectional analysis of 884 young Israeli adults who participated in the population-based Jerusalem Lipid Research Clinic (LRC) study was conducted. Lipoprotein particle size was assessed using proton nuclear magnetic resonance.
RESULTS In multivariable linear regression models that included sex, BMI, waist circumference, homeostasis model assessment of insulin resistance, and leptin, adiponectin was associated with mean LDL size (standardized regression coefficient B = 0.20; P < 0.001), VLDL size (B = −0.12; P < 0.001), and HDL size (B = 0.06; P = 0.013). Adiponectin was inversely related to large VLDL (P < 0.001) but positively to small VLDL (P = 0.02), inversely related to small LDL (P < 0.006) but positively to large LDL (P < 0.001), and positively related to large HDL (P < 0.001) subclass concentrations.
CONCLUSIONS Adiponectin is favorably associated with lipoprotein particle size and subclass distribution independent of adiposity and insulin sensitivity.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Received January 16, 2009.
- Accepted April 14, 2009.
-
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
- © 2009 by the American Diabetes Association.
